Prostate cancer screening: Facts, statistics, and interpretation in response to the US Preventive Services Task Force review

Journal of Clinical Oncology

Volumn 30, Issue 21, 2012, Pages 2581-2584

  Carlsson, Sigrid ^a,b   Vickers, Andrew J ^a   Roobol, Monique ^c   Eastham, James ^a   Scardino, Peter ^d   Lilja, Hans ^a,b,e   Hugosson, Jonas ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d LUND UNIVERSITY   (Sweden)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; DISEASE COURSE; HUMAN; MALE; NOTE; PATIENT REFERRAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES;

ADVISORY COMMITTEES; AGE FACTORS; AGED; CLINICAL TRIALS AS TOPIC; DATA INTERPRETATION, STATISTICAL; EARLY DETECTION OF CANCER; HUMANS; MALE; META-ANALYSIS AS TOPIC; MODELS, STATISTICAL; PRIMARY PREVENTION; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REFERRAL AND CONSULTATION; RISK FACTORS; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES; WATCHFUL WAITING;

EID: 84864088954     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.4327     Document Type: Note

References (41)

1. Chou R, Croswell JM, Dana T, et al: Screening for prostate cancer: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 155:762-771, 2011
2. Moyer VA, US Preventive Services Task Force: Screening for prostate cancer: US Preventive Services Task Force recommendation statement. Ann Intern Med [epub ahead of print on May 21, 2012]
3. Schröder FH, Hugosson J, Roobol MJ, et al: Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328, 2009
4. Schröder FH, Hugosson J, Roobol MJ, et al: Prostate-cancer mortality at 11 years of follow-up. N Engl J Med 366:981-990, 2012
5. Hugosson J, Carlsson S, Aus G, et al: Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11:725-732, 2010
6. Djulbegovic M, Beyth RJ, Neuberger MM, et al: Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ 341:c4543, 2010
7. Ilic D, O'Connor D, Green S, et al: Screening for prostate cancer: An updated Cochrane systematic review. BJU Int 107:882-891, 2011
8. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319, 2009
9. Andriole GL, Crawford ED, Grubb RL 3rd, et al: Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality results after 13 years of follow-up. J Natl Cancer Inst 104:125-132, 2012
10. Schröder FH, Roobol MJ: ERSPC and PLCO prostate cancer screening studies: What are the differences? Eur Urol 58:46-52, 2010
11. Pinsky PF, Blacka A, Kramer BS, et al: Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials 7:303-311, 2010
12. Loeb S, Vonesh EF, Metter EJ, et al: What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 29:464-467, 2011
13. Gulati R, Mariotto AB, Chen S, et al: Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol 64:1412-1417, 2011
14. Macefield RC, Lane JA, Metcalfe C, et al: Do the risk factors of age, family history of prostate cancer or a higher prostate specific antigen level raise anxiety at prostate biopsy? Eur J Cancer 45:2569-2573, 2009
15. Carlsson S, Aus G, Wessman C, et al: Anxiety associated with prostate cancer screening with special reference to men with a positive screening test (elevated PSA): Results from a prospective, population-based, randomised study. Eur J Cancer 43:2109-2116, 2007 (Pubitemid 47380358)
16. Essink-Bot ML, de Koning HJ, Nijs HG, et al: Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 90:925-931, 1998 (Pubitemid 28304162)
17. Brindle LA, Oliver SE, Dedman D, et al: Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK. BJU Int 98:777-782, 2006 (Pubitemid 44368024)
18. Yao SL, Lu-Yao G: Population-based study of relationships between hospital volume of prostatectomies, patient outcomes, and length of hospital stay. J Natl Cancer Inst 91:1950-1956, 1999
19. Lu-Yao GL, Albertsen P, Warren J, et al: Effect of age and surgical approach on complications and short-term mortality after radical prostatectomy: A population-based study. Urology 54:301-307, 1999 (Pubitemid 29367256)
20. Lu-Yao GL, McLerran D, Wasson J, et al: An assessment of radical prostatectomy: Time trends, geographic variation, and outcomes - The Prostate Patient Outcomes Research Team. JAMA 269:2633-2636, 1993
21. Carlsson S, Adolfsson J, Bratt O, et al: Nationwide population-based study on 30-day mortality after radical prostatectomy in Sweden. Scand J Urol Nephrol 43:350-356, 2009
22. McNaughton-Collins MF, Barry MJ: One man at a time: Resolving the PSA controversy. N Engl J Med 365:1951-1953, 2011
23. Drazer MW, Huo D, Schonberg MA, et al: Population-based patterns and predictors of prostate-specific antigen screening among older men in the United States. J Clin Oncol 29:1736-1743, 2011
24. Sima CS, Panageas KS, Schrag D: Cancer screening among patients with advanced cancer. JAMA 304:1584-1591, 2010
25. Kawachi MH, Bahnson RR, Barry M, et al: NCCN clinical practice guidelines in oncology: Prostate cancer early detection. J Natl Compr Canc Netw 8:240-262, 2010
26. Schröder FH, Roobol-Bouts M, Vis AN, et al: Prostate-specific antigen-based early detection of prostate cancer: Validation of screening without rectal examination. Urology 57:83-90, 2001 (Pubitemid 32065825)
27. Vickers AJ, Till C, Tangen CM, et al: An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst 103:462-469, 2011
28. Carlsson S: Prostate cancer screening with PSA: A study of potential negative consequences. Gothenburg, Sweden, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, 2010. http://hdl.handle.net/ 2077/21922
29. Fowler FJ Jr, McNaughton Collins M, Albertsen PC, et al: Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA 283:3217-3222, 2000 (Pubitemid 30422039)
30. Cooperberg MR, Broering JM, Kantoff PW, et al: Contemporary trends in low risk prostate cancer: Risk assessment and treatment. J Urol 178:S14-S19, 2007 (Pubitemid 47224952)
31. Savage CJ, Vickers AJ: Low annual caseloads of United States surgeons conducting radical prostatectomy. J Urol 182:2677-2679, 2009
32. Begg CB, Riedel ER, Bach PB, et al: Variations in morbidity after radical prostatectomy. N Engl J Med 346:1138-1144, 2002 (Pubitemid 34984605)
33. Vickers AJ, Bianco FJ, Serio AM, et al: The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 99:1171-1177, 2007 (Pubitemid 47233067)
34. Zietman AL, DeSilvio ML, Slater JD, et al: Comparison of conventionaldose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA 294:1233-1239, 2005 (Pubitemid 41352111)
35. Lilja H, Cronin AM, Dahlin A, et al: Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. Cancer 117:1210-1219, 2011
36. Vickers AJ, Cronin AM, Bjork T, et al: Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study. BMJ 341:c4521, 2010
37. Roobol MJ, Roobol DW, Schröder FH: Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam). Urology 65:343-346, 2005 (Pubitemid 40248025)
38. Memorial Sloan-Kettering Cancer Center: Screening guidelines: Prostate cancer. http://www.mskcc.org/cancer-care/screening-guidelines/screening- guidelines-prostate
39. Klotz L, Zhang L, Lam A, et al: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131, 2010
40. Lu-Yao GL, Albertsen PC, Moore DF, et al: Outcomes of localized prostate cancer following conservative management. JAMA 302:1202-1209, 2009
41. Eastham JA: Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol 27:417-421, 2009